There’s “abundant preclinical literature demonstrating the anti-inflammatory effects of cannabinoid drugs in inflammation of the gut”, according to a new study published by the journal Inflammatory Bowel Disease.
For the study, researchers “systematically reviewed publications on the benefit of drugs targeting the endo-cannabinoid system in intestinal inflammation.” They “collated studies examining outcomes for meta-analysis from EMBASE, MEDLINE and Pubmed until March 2017. Quality was assessed according to mSTAIR and SRYCLE score.”
For the study, “51 publications examining the effect of cannabinoid compounds on murine colitis and 2 clinical studies were identified. Twenty-four compounds were assessed across 71 endpoints. Cannabidiol, a phytocannabinoid, was the most investigated drug.”